- Home
- PVL vs BEAT Comparison
PVL vs BEAT Comparison
Compare PVL & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | BEAT |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 48.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVL | BEAT |
|---|---|---|
| Price | $1.94 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 124.0K | ★ 1.2M |
| Earning Date | 03-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $0.54 |
| 52 Week High | $2.04 | $4.00 |
Technical Indicators
Market Signals| Indicator | PVL | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 49.69 |
| Support Level | $1.75 | $0.91 |
| Resistance Level | $2.03 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 56.25 | 53.85 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.